Results 101 to 110 of about 18,511 (201)

Grape Pomace as a Source of Phenolics for the Inhibition of Starch Digestion Enzymes: A Comparative Study and Standardization of the Efficacy

Foods
The increase in the incidence of hyperglycemia and diabetes poses the challenge of finding cost-effective natural inhibitors of starch digestion enzymes. Among natural compounds, phenolics have been considered as promising candidates.
Pedapati Siva Charan Sri Harsha, Vera Lavelli   +1 more
doaj   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8172-8188, September 2026.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux, Dongkun Lee, Jeff M. Phillips, Julio C. Facelli, Daniel C. Malone, Matthew Wahl, Deepika Reddy, Farrant Sakaguchi, Ramkiran Gouripeddi, Alexander S. Millar, Matthew J. O'Brien, Joshua S. Choi, Jittrapol Sutejitsiri, Kensaku Kawamoto, Polina V. Kukhareva   +14 more
wiley   +1 more source

Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population‐Based Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8460-8468, September 2026.
ABSTRACT Aims This study aimed to analyse incident glucose lowering drug (GLD) utilisation in Australia between the period 2014 and 2024. Materials and Methods Australian Pharmaceutical Benefits Scheme (PBS) data (10% PBS dataset) were analysed to assess the proportions of incident monotherapy, dual therapy and triple therapy and the proportion of ...
Peter S. Hamblin, Stella Talic, Harvey J. W. Koh, Arul Earnest, Anthony W. Russell, Sophia Zoungas   +5 more
wiley   +1 more source

Waist‐to‐height ratio and renal dysfunction as independent correlates of low handgrip strength in patients with type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1538-1547, September 2026.
In 1,468 patients with type 2 diabetes, central obesity (WHtR >0.5) neutralizes the protective effects of higher BMI on muscle strength. Concurrently, visceral adiposity and CKD impose an additive threat, maximizing low handgrip strength risk (aOR = 1.74). Combining WHtR and renal tracking optimizes clinical sarcopenia screening.
Shing‐Hua Chen, Chen‐Kai Chou, Shao‐Wen Weng, Jung‐Fu Chen, Feng‐Chih Shen   +4 more
wiley   +1 more source

Acarbose treatment in obesity: a controlled study.

, 1998
Acarbose is an alpha-glucosidase inhibitor which reversibly inhibits oligosaccharidase and disaccharidase at the brush border of the small intestine. The aim of this study was to observe its effectiveness in the treatment of obesity.
Ozgen A.G., Yilmaz C., Tüzün M., Hamulu F., Bayraktar F., Kabalak T.   +5 more
core   +1 more source

Acarbose effects on vascular stiffness in patients with arterial hypertension and metabolic syndrome

Кардиоваскулярная терапия и профилактика, 2006
Aim. To assess perspectives of pulse wave velocity (PWV) correction during acarbose treatment in patients with impaired glucose tolerance (IGT) and arterial hypertension (AH). Material and methods.
S. V. Nedogoda, V. A. Tsoma, I. N. Barykina, G. V. Mazina, U. A. Brel, T. A. Chalyabi, V. B. Mychka, I. E. Chazova   +7 more
doaj  

SGLT‐2 inhibitors and high‐dose acarbose as potential high‐risk combinations for ketosis and ketoacidosis in Asian patients with T2DM: A case series

Clinical Case Reports
Key Clinical Message High‐dose acarbose may increase the risk of diabetic ketosis/diabetic ketoacidosis in Asian patients on sodium‐glucose cotransporter‐2 inhibitors.
Wei Qiang, Fei Yang, Ling Liu, Ruiqing Dong, Yushi Sun, Ahona Mondal, Hui Guo   +6 more
doaj   +1 more source

Cost Minimization Analysis of Oral Antidiabetic Drugs in Type II Diabetes Mellitus Patiens at Sultan Suriansyah Hospital January-December 2022 Period

Berkala Kedokteran
Diabetes According to WHO (2016) is a serious chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces.
Farah Noor Ain, Saftia Aryzki, Muhammad Mahendra Abdi   +2 more
doaj   +1 more source

Characterization of two coleopteran a-amylases and molecular insights into their differential inhibition by synthetic a-amylase inhibitor, acarbose

, 2016
Post-harvest insect infestation of stored grains makes them unfit for human consumption and leads to severe economic loss. Here, we report functional and structural characterization of two coleopteran α-amylases viz.
Maheshwari, V. L., Kashyap, Garima, Bhide, Amey J., Yadav, Yashpal, Giri, Ashok P., Channale, Sonal M., Pawar, Pankaj K., Ramasamy, Sureshkumar   +7 more
core   +1 more source

Exploring the Bioactivity of Acarbose on Autoimmune Diseases

, 2017
乾癬與類風溼性關節炎由Th1與Th17細胞主導，在臨床上為慢性自體免疫疾病。乾癬典型的病徵為皮膚紅腫、鱗片狀表皮增生和異常角質分化；類風濕性關節炎主要特徵包括關節僵硬變形、滑膜炎、軟骨磨損、類風濕性小結及血管有免疫細胞浸潤。Acarbose具有高耐受性，為常見的降血糖藥物。Acarbose為α-glucosidase inhibitors，會干擾小腸刷毛緣α-glucosidases的作用，阻斷澱粉和蔗糖的降解，進而延緩葡萄糖的吸收。近年來研究發現在第二型糖尿病患者身上 ...
趙雅萱, Ya-Hsuan Chao
core